keyword
MENU ▼
Read by QxMD icon Read
search

Hba1c cardiovascular risk

keyword
https://www.readbyqxmd.com/read/29780322/efficacy-and-safety-of-teneligliptin-in-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#1
REVIEW
Xiaoxuan Li, Xuefei Huang, Chongfei Bai, Dalian Qin, Shousong Cao, Qibing Mei, Yun Ye, Jianming Wu
Background: Teneligliptin is a 3rd-generation dipeptidyl peptidase-4 (DPP-4) inhibitor. There is a limited evidence regarding the effect of teneligliptin. Therefore, this study is to assess the efficacy and safety of teneligliptin in type 2 diabetes mellitus (T2DM) patients with inadequately glycemic controlled. Methods: A search of PubMed, Medline, Embase, and The Cochrane Library during 2000.01-2018.03 was performed for randomized controlled trials of teneligliptin compared to placebo in patients with T2DM with monotherapy or add-on treatment...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29777519/combination-glucose-lowering-therapy-plans-in-t2dm-case-based-considerations
#2
REVIEW
Lawrence Blonde, Susana Dipp, Daniel Cadena
Type 2 diabetes mellitus (T2DM) is a complex disease, and while lifestyle interventions remain the cornerstone of therapy, most patients will also require pharmacotherapy. Current diabetes treatment guidelines and algorithms recommend an individualized approach to setting glycemic goals and selecting treatment. Although a single antihyperglycemic agent may be appropriate as the initial T2DM pharmacotherapy, the progressive nature of the disease due to declining pancreatic β-cell function will result in the vast majority of T2DM patients eventually requiring two or more antihyperglycemic agents...
May 18, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29773079/effects-of-linagliptin-on-endothelial-function-and-postprandial-lipids-in-coronary-artery-disease-patients-with-early-diabetes-a-randomized-placebo-controlled-double-blind-trial
#3
Norbert J Tripolt, Felix Aberer, Regina Riedl, Jasmin Url, Gudrun Dimsity, Andreas Meinitzer, Tatjana Stojakovic, Faisal Aziz, Ronald Hödl, Gabriele Brachtl, Dirk Strunk, Marianne Brodmann, Franz Hafner, Harald Sourij
BACKGROUND: Early glucose lowering intervention in subjects with type 2 diabetes mellitus was demonstrated to be beneficial in terms of micro- and macrovascular risk reduction. However, most of currently ongoing cardiovascular outcome trials are performed in subjects with manifest atherosclerosis and long-standing diabetes. Therefore, the aim of this study is to investigate the effects of the dipeptidylpeptidase-4 inhibitor linagliptin in subjects with coronary artery disease (CAD) but early type 2 diabetes mellitus (T2DM) on a set of cardiovascular surrogate measurements...
May 17, 2018: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29764903/vitamin-d-supplementation-does-not-improve-cvd-risk-factors-in-vitamin-d-insufficient-subjects
#4
Julia Magdalena Kubiak, Per Medbøe Thorsby, Elena Kamycheva, Rolf Jorde
OBJECTIVE: Low serum 25(OH)D levels are associated with cardiovascular disease (CVD) and some of its risk factors. However, in interventional studies the effects of vitamin D supplementation have been uncertain, possibly due to inclusion of vitamin D sufficient subjects. Our aim was therefore to examine effects of vitamin D supplementation on CVD risk factors in vitamin D insufficient subjects. DESIGN: Double-blinded randomized controlled trial. METHODS: A four months interventional study with high dose vitamin D (100 000 IU loading dose, followed by 20 000 IU/week) or placebo with measurements of blood pressure, lipids (total-, LDL- and HDL-cholesterol, triglycerides, apolipoproteins A1 and B), and glucose metabolism parameters (blood glucose, HbA1c, sRAGE, insulin, C-peptide, and HOMA-IR)...
May 15, 2018: Endocrine Connections
https://www.readbyqxmd.com/read/29764225/initial-combination-therapy-with-vildagliptin-plus-metformin-in-drug-na%C3%A3-ve-patients-with-t2dm-a-24-week-real-life-study-from-asia
#5
Manoj Chawla, Tae Ho Kim, Roberto C Mirasol, Pathan Faruque, Kathryn Cooke, Peggy Hours-Zesiger, Abhijit Shete
AIMS: To assess the effectiveness and safety of vildagliptin/metformin initial combination therapy in drug-naïve patients with type 2 diabetes mellitus (T2DM). METHODS: INITIAL was a 24-week prospective, observational study in T2DM patients with glycated hemoglobin (HbA1c) ≥7.5%, and prescribed vildagliptin/metformin as initial combination therapy. The primary endpoint was change in HbA1c from baseline to week 24. Key secondary endpoints were HbA1c change from baseline to week 12, proportion of patients achieving HbA1c ≤7...
May 15, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29760188/depression-in-type-1-diabetes-was-associated-with-high-levels-of-circulating-galectin-3
#6
Eva O Melin, Jonatan Dereke, Maria Thunander, Magnus Hillman
OBJECTIVE: Neuroinflammatory responses are implicated in depression. The aim was to explore whether depression in patients with type 1 diabetes (T1D) was associated with high circulating galectin-3, controlling for metabolic variables, s-creatinine, life style factors, medication, and cardiovascular complications. DESIGN: Cross-sectional. METHODS: Participants were T1D patients (n=283, 56% men, age 18-59 years, diabetes duration ≥1 year)...
May 14, 2018: Endocrine Connections
https://www.readbyqxmd.com/read/29754804/diabetes-mellitus-and-cardiovascular-risk-update-of-the-recommendations-of-the-diabetes-and-cardiovascular-disease-working-group-of-the-spanish-diabetes-society-sed-2018
#7
Francisco Arrieta, Pedro Iglesias, Juan Pedro-Botet, Antonio Becerra, Emilio Ortega, Juan Carlos Obaya, Andreu Nubiola, Gonzalo Fernando Maldonado, Maria Del Mar Campos, Romina Petrecca, José Luis Pardo, Víctor Sánchez-Margalet, José Juan Alemán, Jorge Navarro, Santiago Duran, Francisco Javier Tébar, Manuel Aguilar, Fernando Escobar
This document is an update to the clinical practice recommendations for the management of cardiovascular risk factors in diabetes mellitus. The consensus is made by members of the Cardiovascular Risk Group of the Spanish Diabetes Society. We have proposed and updated interventions on lifestyle, pharmacological treatment indicated to achieve therapeutic objectives according to the levels of HbA1c, degree of obesity, hypertension, hyperlipidemia, heart failure, platelet antiagregation, renal insufficiency, and diabetes in the elderly, as well as new biomarkers of interest in the evaluation of cardiovascular risk in individuals with diabetes mellitus...
May 10, 2018: Clínica e Investigación en Arteriosclerosis
https://www.readbyqxmd.com/read/29754649/telemedicine-cardiovascular-risk-reduction-in-veterans-the-cities-trial
#8
Hayden B Bosworth, Maren K Olsen, Felicia McCant, Karen M Stechuchak, Susanne Danus, Matthew J Crowley, Karen M Goldstein, Leah L Zullig, Eugene Z Oddone
BACKGROUND: Comprehensive programs addressing tailored patient self-management and pharmacotherapy may reduce barriers to cardiovascular disease (CVD) risk reduction. METHODS: This is a 2-arm (clinical pharmacist specialist-delivered, telehealth intervention and education control) randomized controlled trial including Veterans with poorly controlled hypertension and/or hypercholesterolemia. Primary outcome was Framingham CVD risk score at 6 and 12 months, with systolic blood pressure; diastolic blood pressure; total cholesterol; low-density lipoprotein; high-density lipoprotein; body mass index; and, for those with diabetes, HbA1c as secondary outcomes...
May 2018: American Heart Journal
https://www.readbyqxmd.com/read/29754570/cardiovascular-risk-factors-in-a-child-population-the-health-oriented-pedagogical-project-hopp
#9
Wei Hai Deng, Morten Lindberg, Ole Petter Hjelle, Asgeir Mamen, Per Morten Fredriksen
AIMS: The main aim of the present study was to investigate the clustering of risk factors for cardiovascular diseases and metabolic syndrome in a large, healthy representative Norwegian child population. METHODS: From a population of 2817, parents of 2297 children agreed to participate. Values of waist circumference (WC), total cholesterol (TC), high-density lipoprotein (HDL), systolic blood pressure (sysBP), haemoglobin-A1c (HbA1c) and Andersen aerobic fitness test were used to test clustering of cardiometabolic risk factors in this sample...
May 2018: Scandinavian Journal of Public Health
https://www.readbyqxmd.com/read/29752393/cardiac-structural-remodeling-longitudinal-systolic-strain-and-torsional-mechanics-in-lean-and-nonlean-dysglycemic-chinese-adults
#10
Jiun-Lu Lin, Kuo-Tzu Sung, Cheng-Huang Su, Tzu-Hsun Chou, Chi-In Lo, Jui-Peng Tsai, Shun-Chuan Chang, Yau-Huei Lai, Kuang-Chun Hu, Chia-Yuan Liu, Chun-Ho Yun, Chung-Lieh Hung, Hung-I Yeh, Carolyn S P Lam
BACKGROUND: Diabetes mellitus and pre-diabetes mellitus are associated with lower body mass indices and increased risk of cardiovascular events (including heart failure) at lower glucose thresholds in Chinese compared with Western cohorts. However, the extent of cardiac remodeling and regulation on cardiac mechanics in lean and nonlean dysglycemic Chinese adults is understudied. METHODS AND RESULTS: We studied 3950 asymptomatic Chinese (aged 49.7±10.7 years; 65% male; body mass index: 24...
May 2018: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29750655/metabolic-risk-factors-in-adolescent-girls-with-type-1-diabetes
#11
Cíntia Castro-Correia, Rita Santos-Silva, Marta Pinheiro, Carla Costa, Manuel Fontoura
BACKGROUND: The incidence of pediatric metabolic syndrome (MS) has progressively increased. The incidence of type 1 diabetes mellitus (T1DM) has also increased. Thus, some children and adolescents with T1DM exhibit MS parameters. The aim of the study was to evaluate the presence of MS parameters in female adolescents with T1DM based on their nutritional status. METHODS: We evaluated 44 adolescents with T1DM (consecutive non-randomized sample) aged between 14 and 18 years, who were on intensive therapy with insulin...
May 11, 2018: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/29750228/hypertension-among-newly-diagnosed-diabetic-patients-at-mulago-national-referral-hospital-in-uganda-a-cross-sectional-study
#12
Martin Muddu, Edrisa Mutebi, Isaac Ssinabulya, Samuel Kizito, Charles Kiiza Mondo
BACKGROUND: The prevalence of hypertension in patients with diabetes is approximately two-fold higher than in age-matched subjects without the disease and, conversely, individuals with hypertension are at increased risk of developing diabetes compared with normotensive persons. Up to 75% of cases of cardiovascular disease (CVD) in patients with diabetes are attributed to hypertension. Diabetics who have hypertension are more likely to develop complications and die, and appropriate blood pressure control in these individuals reduces the risk...
April 20, 2018: Cardiovascular Journal of Africa
https://www.readbyqxmd.com/read/29749131/the-impact-of-prediabetes-on-two-year-clinical-outcomes-in-patients-undergoing-elective-percutaneous-coronary-intervention
#13
Woong Gil Choi, Seung Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Ahmed Mashaly, Yoonjee Park, Won Young Jang, Woohyeun Kim, Jah Yeon Choi, Eun Jin Park, Jin Oh Na, Cheol Ung Choi, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo
PURPOSE: Prediabetes is an independent risk factor for cardiovascular disease. However, data on the long term adverse clinical outcomes of prediabetic patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) are scarce. MATERIALS AND METHODS: The study population comprised 674 consecutive non-diabetic patients who underwent elective PCI between April 2007 and November 2010. Prediabetes was defined as hemoglobin A1c (HbA1c) of 5...
June 2018: Yonsei Medical Journal
https://www.readbyqxmd.com/read/29741271/new-onset-diabetes-mellitus-among-patients-with-glomerular-diseases
#14
Cynthia C Lim, Maggie Wy Wong, Hui Ling Koh, Yok Mooi Chin, Irene Yj Mok, Jason Cj Choo
BACKGROUND: Glomerulonephritis commonly causes kidney failure. Immunosuppressant treatment may be diabetogenic but data on hyperglycemia in glomerulonephritis treated with usual clinical care is scanty. AIM: We aimed to assess the epidemiology, risk factors and outcomes for New-Onset Diabetes among patients with Glomerular disease (NODAG). METHODS: Single-centre retrospective cohort of non-diabetic adults diagnosed with glomerulonephritis between January 2011 and July 2015...
May 9, 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29739781/multiple-risk-factor-control-mortality-and-cardiovascular-events-in-type-2-diabetes-and-chronic-kidney-disease-a-population-based-cohort-study
#15
Shota Hamada, Martin C Gulliford
OBJECTIVES: This study aimed to evaluate the effectiveness of multiple risk factor control (MRFC) at reducing mortality and cardiovascular events in diabetes and chronic kidney disease (CKD) in clinical practice. DESIGN: Population-based cohort study. SETTING: Primary care database in the UK, linked with inpatient and mortality data. PARTICIPANTS: Participants aged 40-79 years with type 2 diabetes and valid serum creatinine measurements, including 11 431 participants with CKD (estimated glomerular filtration rate: eGFR 15-59 mL/min/1...
May 8, 2018: BMJ Open
https://www.readbyqxmd.com/read/29735306/renoprotective-effects-of-sodium-glucose-cotransporter-2-inhibitors
#16
REVIEW
Hiddo J L Heerspink, Mikhail Kosiborod, Silvio E Inzucchi, David Z I Cherney
Over the past two years, our understanding of anti-hyperglycemic medications used to treat patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG OUTCOME trial, agents used to lower blood glucose were felt to prevent or delay the development of microvascular complications, but were not known to definitively reduce cardiovascular risk or mortality. Previous studies with then novel sodium-glucose cotransport-2 (SGLT2) inhibitors demonstrated improvements in several cardiovascular and renal risk factors, including HbA1c, blood pressure, weight, renal hyperfiltration, and albuminuria...
May 5, 2018: Kidney International
https://www.readbyqxmd.com/read/29734470/interventions-for-improving-modifiable-risk-factor-control-in-the-secondary-prevention-of-stroke
#17
REVIEW
Bernadeta Bridgwood, Kate E Lager, Amit K Mistri, Kamlesh Khunti, Andrew D Wilson, Priya Modi
BACKGROUND: People with stroke or transient ischaemic attack (TIA) are at increased risk of future stroke and other cardiovascular events. Stroke services need to be configured to maximise the adoption of evidence-based strategies for secondary stroke prevention. Smoking-related interventions were examined in a separate review so were not considered in this review. This is an update of our 2014 review. OBJECTIVES: To assess the effects of stroke service interventions for implementing secondary stroke prevention strategies on modifiable risk factor control, including patient adherence to prescribed medications, and the occurrence of secondary cardiovascular events...
May 7, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29733433/statin-therapy-on-glycemic-control-in-type-2-diabetic-patients-a-network-meta-analysis
#18
J Y Cui, R R Zhou, S Han, T S Wang, L Q Wang, X H Xie
WHAT IS KNOWN AND OBJECTIVE: Statins are the cornerstone of primary and secondary prevention of cardiovascular diseases (CVDs) and are effective for the prevention of vascular events in diabetic patients. Diabetes mellitus is an important risk factor for CVDs .The majority of patients with diabetes mellitus benefits from statin therapy. According to the recent clinical guidelines of the American College of Cardiology and the American Heart Association, moderate-intensity or high-intensity statin therapy should be used as the primary prevention for individuals with diabetes mellitus, aged between 40 and 75 years and with low-density lipoprotein cholesterol (LDL-C) from 70 to 189 mg/dL...
May 7, 2018: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29730388/are-the-favorable-cardiovascular-outcomes-of-empagliflozin-treatment-explained-by-its-effects-on-multiple-cardiometabolic-risk-factors-a-simulation-of-the-results-of-the-empa-reg-outcome-trial
#19
Shihchen Kuo, Wen Ye, Justin Duong, William H Herman
AIMS: It is unclear whether the favorable impact of empagliflozin on cardiovascular outcomes (CVOs) is due to its effect on multiple cardiometabolic risk factors (CRFs). METHODS: We used the Michigan Model for Diabetes, a validated computer simulation model, and published data from the EMPA-REG OUTCOME trial to estimate three-year CVOs in the placebo and pooled empagliflozin treatment groups to assess whether the observed benefits might be attributable to differences in CRFs...
May 3, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29729825/a-randomized-controlled-trial-of-an-intensive-nutrition-intervention-versus-standard-nutrition-care-to-avoid-excess-weight-gain-after-kidney-transplantation-the-intent-trial
#20
Cordula K Henggeler, Lindsay D Plank, Kristin J Ryan, Emily L Gilchrist, Jessie M Casas, Lyn E Lloyd, Laura E Mash, Sandra L McLellan, Jennifer M Robb, Michael G Collins
OBJECTIVE: Excessive weight gain is common after kidney transplantation and increases cardiovascular risk. The aim of this randomized controlled trial was to determine whether an intensive nutrition and exercise intervention delivered alongside routine post-transplant care would reduce post-transplant weight gain. DESIGN: Single-blind, randomized controlled trial. SUBJECTS AND SETTING: Adult kidney transplant recipients at a regional transplant center were recruited during routine outpatient clinic visits in the first month after transplant...
May 2, 2018: Journal of Renal Nutrition
keyword
keyword
18436
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"